November 24, 2009 10:30 AM
- Text
Faster-Working Erectile Dysfunction Drug?
- Adele's Grammy Comeback After Vocal Cord Surgery
- Treating Sleep Apnea in Kids Improves Behavior, Quality of Life
- Chemo May Not Harm Unborn Baby
- C-Sections Not Always Best for Small Babies
- CDC: Doctors Increasingly Prescribe Exercise
- Osteoporosis Medication Linked to Unusual Thigh Fractures
- More from WebMD »
Couple kisses, erectile dysfunction, medications (AP / CBS)
(WebMD)
An experimental erectile dysfunction drug - avanafil - promises erections in just 30 minutes or less, according to a study by the drug's manufacturer.
The phase 3 study, not yet published in a peer-reviewed scientific journal, included 646 men with erectile dysfunction (ED). At the highest dose tested (200 milligrams), nearly 80 percent of sexual attempts resulted in erections good enough for intercourse.
Study investigator LeRoy Jones, MD, associate professor of urology at the University of Texas Health Science Center, said the new drug will offer a new alternative to men seeking "an improved experience" with current erectile dysfunction drugs.
"These data suggesting that avanafil achieves a full effect in 30 minutes or less, with a window of opportunity extending beyond six hours, would be a welcome option for ED treatment ," Jones said in a news release from Vivus Inc., which has licensed the drug from Mitsubishi Tanabe Pharma Corp.
In the study, men received either an inactive placebo or avanafil at a dose of 50 milligrams, 100 milligrams, or 200 milligrams. Successful intercourse was reported by:
-27 percent of men taking placebo (up from 13 percent at the start of the study)
-41 percent of men taking avanafil 50 milligrams (up from 13 percent at the start of the study)
-57 percent of men taking avanafil 100 milligrams (up from 14 percent at the start of the study)
-57 percent of men taking avanafil 200 milligrams (up from 12 percent at the start of the study)
Avanafil's most frequent side effect was headache, reported by 7 percent of men receiving the drug and by 1.2 percent of men taking placebo. Other common side effects included flushing (4.6 percent of men on avanafil vs. none on placebo) and nasal congestion (2.3 percent of men on avanafil vs. 1.2 percent on placebo).
Avanafil works the same way as the three other ED drugs currently on the market: Viagra, Cialis, and Levitra . All these drugs target an enzyme called PDE5; avanafil appears to inhibit this enzyme more selectively than the other.
A Vivus news release suggests that in addition to working faster than Viagra, Cialis, and Levitra, the new drug may have fewer side effects.
The current study, dubbed REVIVE, is the first of four phase 3 trials of avanafil. Two of the other studies will look at how well the drug helps erectile dysfunction in men with diabetes and in men who have had prostate surgery. A third study, enrolling 600 men at 40 U.S. medical centers, began in March 2009 and will continue for one year.
Vivus expects to submit avanafil for FDA approval in late 2010 or early 2011.
By Daniel DeNoon
Reviewed by Louise Chang
©2005-2008 WebMD, LLC. All rights reserved
The phase 3 study, not yet published in a peer-reviewed scientific journal, included 646 men with erectile dysfunction (ED). At the highest dose tested (200 milligrams), nearly 80 percent of sexual attempts resulted in erections good enough for intercourse.
Study investigator LeRoy Jones, MD, associate professor of urology at the University of Texas Health Science Center, said the new drug will offer a new alternative to men seeking "an improved experience" with current erectile dysfunction drugs.
"These data suggesting that avanafil achieves a full effect in 30 minutes or less, with a window of opportunity extending beyond six hours, would be a welcome option for ED treatment ," Jones said in a news release from Vivus Inc., which has licensed the drug from Mitsubishi Tanabe Pharma Corp.
In the study, men received either an inactive placebo or avanafil at a dose of 50 milligrams, 100 milligrams, or 200 milligrams. Successful intercourse was reported by:
-27 percent of men taking placebo (up from 13 percent at the start of the study)
-41 percent of men taking avanafil 50 milligrams (up from 13 percent at the start of the study)
-57 percent of men taking avanafil 100 milligrams (up from 14 percent at the start of the study)
-57 percent of men taking avanafil 200 milligrams (up from 12 percent at the start of the study)
Avanafil's most frequent side effect was headache, reported by 7 percent of men receiving the drug and by 1.2 percent of men taking placebo. Other common side effects included flushing (4.6 percent of men on avanafil vs. none on placebo) and nasal congestion (2.3 percent of men on avanafil vs. 1.2 percent on placebo).
Avanafil works the same way as the three other ED drugs currently on the market: Viagra, Cialis, and Levitra . All these drugs target an enzyme called PDE5; avanafil appears to inhibit this enzyme more selectively than the other.
A Vivus news release suggests that in addition to working faster than Viagra, Cialis, and Levitra, the new drug may have fewer side effects.
The current study, dubbed REVIVE, is the first of four phase 3 trials of avanafil. Two of the other studies will look at how well the drug helps erectile dysfunction in men with diabetes and in men who have had prostate surgery. A third study, enrolling 600 men at 40 U.S. medical centers, began in March 2009 and will continue for one year.
Vivus expects to submit avanafil for FDA approval in late 2010 or early 2011.
By Daniel DeNoon
Reviewed by Louise Chang
©2005-2008 WebMD, LLC. All rights reserved
Popular Now in Health
- Cancer drug reverses Alzheimer's in mice: Study
- Marijuana-smoking motorists twice as likely to crash
- Norovirus outbreak hits Rider University in N.J
- America's pets also have an obesity epidemic
- 4.5 million Americans over 50 have artificial knees
- Skin cancer self-exam: What to look for (PHOTOS)
- Caffeine inhalers - the next club drug?
- Things You Didn't Know About Your Penis
- Chinese mom gives birth to 15-pound baby
- America's sodium problem: Not from salty snacks?
- Measles patient at Super Bowl prompts health alert
- Let's Move! campaign turns 2 today: Is it working?
- PICTURES: 15 Shocking Sexual Fetishes
- John Dye Dies: What Killed "Angel" Star?
- Woman spotlights uterus didelphys on talk show
- 8 Tips For Losing Weight After Pregnancy
- Christina Hendricks: Too Big for Hollywood?
Latest CBS News Headlines
on Facebook
on CBS News
- Guatemalan President to propose legalizing drugs
- Faces beyond the numbers of long-term unemployed
- Money fund assets fall to $2.657 trillion
- Obama budget: New spending with recycled tax ideas
on Facebook
- Adele sings a cappella for Anderson Cooper
- Occupy protestors kicked out of CPAC
- CPAC: Will Sarah Palin spring a surprise?
- Beyonce and Jay-Z post first photos of Blue Ivy Carter
on CBS News






